Section 23

Lirum Therapeutics to Present Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against Adult and Pediatric IGF-Related Cancers, at the 2024 AACR Annual Meeting

Retrieved on: 
목요일, 4월 4, 2024
Malignancy, Head, Neuroblastoma, Section 23, Breast, Sarcoma, AACR, Therapy, Cancer, Poster, Neck

Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement.

Key Points: 
  • Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement.
  • In particular, these malignancies have known genetic alterations affecting the IGF-1R pathway and/or high IGF-1R expression tied to poor outcomes.
  • Given these promising results and the existing clinical data, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway.
  • Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated.

Syncell Showcases Pioneering Microscopy-Guided Subcellular Protein Scooping Technology at the AACR Annual Meeting 2023

Retrieved on: 
월요일, 4월 10, 2023
Technology, Biotechnology, Health, Biometrics, Pharmaceutical, Artificial Intelligence, Oncology, Other Science, Research, Medical Devices, Software, Genetics, Health Technology, Science, PM, GRASP, Section, Section 23, Protein, Poster, AI

Syncell, a biotech company pioneering in platforms for hypothesis-free spatial proteomics, will be exhibiting and presenting a poster at the AACR Annual Meeting 2023 in Orlando, FL.

Key Points: 
  • Syncell, a biotech company pioneering in platforms for hypothesis-free spatial proteomics, will be exhibiting and presenting a poster at the AACR Annual Meeting 2023 in Orlando, FL.
  • Syncell’s Microscoop technology enables microscopy-guided subcellular protein scooping in ultra-content powered by AI to collect enough proteins for subsequent spatial proteomic identification.
  • Syncell announces that Microscoop Mint, the first commercial Microscoop platform of Syncell, will be available for order.
  • “Syncell’s Microscoop technology is not really a spatial proteomic mapping technology, it is a direct spatial proteomic discovery technology to help researchers identify novel protein biomarkers.

New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services

Retrieved on: 
금요일, 4월 8, 2022
Surface plasmon resonance, Company, Section 23, AM, Syngenic, Central Waqf Council, PM, 2D, Section 27 of the Canadian Charter of Rights and Freedoms, Systems biology, 3D, Section 40 of the Constitution of Australia, Section 39 of the Constitution of Australia, Comparison, PCR, Section 4, KRAS, AACR, Reaction, American Association, Neoplasm, 2021 Essex County Council election, Section 8, Association, American Association for Cancer Research, Section 24 of the Constitution of Australia, CDK, CRO, Section 11 of the Canadian Charter of Rights and Freedoms, Drug discovery, LRRK2, Section 5, Protein kinase, Pharmaceutical industry, Powder metallurgy, Electric motor, Online gambling

MALVERN, Pa., April 8, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry- leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

Key Points: 
  • "At AACR 2022, we look forward to showcasing data from our comprehensive suite of innovative drug discovery services that continue to support our clients in their oncology research goals," said Haiching Ma, Ph.D., Chief Scientific Officer of Reaction Biology.
  • "With these data, we continue to build upon our capabilities as a world leader and partner in drug discovery."
  • Reaction will present data from a number of new and enhanced assays and other drug discovery services in oncology.
  • "These data at AACR represent the breadth and depth of Reaction Biology's pre-clinical research services in oncology and underscore why we are a preferred global partner in the area of drug discovery."